In a word, the data suggested that blocking the ERK1/2-HIF-1α-VEGF/VEGFR2 signaling pathway might be an important mechanism of erianin in diabetic retinopathy therapy (YU et al., 2016). The gene discussed is MAPK3; the disease is diabetic retinopathy.